We have read with interest the editorial of Vaduganathan et al. (1). We strongly agree with the authors regarding the importance for our patients and our health care system of reducing readmissions for heart failure among those initially admitted to hospital, as well as reducing initial admissions. In addition, we
recognize the appropriateness of the authors' caveat regarding potential benefits of devices, educational initiatives and other nonpharmacological approaches when drugs also are used. Nonetheless, given recent publications in this field, including our own, we believe the authors may wish to reconsider some of their statements about strategies for reduction in early readmissions.
First, the authors indicate that the use of ivabradine, which we have specifically assessed in the 6,505-patient SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial), had no impact on early readmissions. They inferred this from "inspection of the survival curves" in the initial SHIFT study report by Swedberg et al. (2) . However, this publication is not at all relevant to the readmission issue because it presents only time-to-first-event analyses of the primary composite endpoint (cardiovascular mortality or heart failure hospitalizations) and of the secondary endpoint of heart failure hospitalizations alone, both of which were markedly and significantly reduced by ivabradine (hospitalizations by 26%). No data of any kind about readmissions were presented. Nonetheless, based on the same concern about the need to reduce readmissions indicated by Vaduganathan et al. (1) , more than a year ago we published a post-hoc analysis of the SHIFT study data focusing specifically on hospital readmissions among the 1,186 patients who, throughout the full duration of the SHIFT study, were admitted to the hospital for worsening heart failure at least once (3) . This study revealed a 34% reduction in second heart failure hospitalizations among those who were admitted once and a 29% reduction in readmissions among those who, despite the initial benefit, were admitted twice. All-cause and cardiovascular hospitalizations were reduced in parallel. Moreover, in addition to assessing admissions using a "total time" approach encompassing all admissions for all patients throughout the trial, we also specifically evaluated time to a second admission with a "gap time" (1) raises important and thought-provoking hypotheses. However, until these are formally tested in appropriately designed trials, it seems reasonable to infer from firm data that therapeutic heart rate slowing with ivabradine, on a background of beta-blockade, angiotensin receptor blockers, or angiotensin-converting enzyme inhibitors; MRAs; and diuretics, is highly likely to reduce both early and late readmission rates for systolic heart failure. 
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